Translating Evidence to Practice: A Case-Based Approach to VTE Prevention, Diagnosis & Management (Accreditation Expired) Faculty: Samuel Goldhaber, MD, | Ruth B. Morrison, RN, BSN, CVN | James B. Groce, III, PharmD, CACP | Sylvia McKean, MD CME credit hour: 2.0
This case-based educational program will help you to identify and discuss pertinent clinical data for the treatment and prevention of VTE, as well as demonstrate how these data can be interpreted and applied into clinical practice. This would include discussion of current issues and controversies surrounding management of VTE, identifying risk factors for VTE, the treatment and secondary prophylaxis in VTE, treatment options for the management of acute PE, as well a special consideration for the medically ill or patients with comorbidities. By reviewing specific patient cases, our esteemed faculty will provide concise and contemporary insight addressing concerns practitioners have regarding the management of patients with VTE.
Chemotherapy-Induced Neutropenia Prevention: Implications of New Clinical Data and Guidelines Faculty: Jeffrey C. Crawford, MD | David C. Dale, MD | Gary H. Lyman, MD, MPH, FRCP (Edin) | Christopher R. Friese, RN, PhD, AOCN® CME / CE credit hour: 1.0
Chemotherapy-induced neutropenia has very serious and important clinical consequences in terms of medical care, quality of life, and economic factors for cancer treatment. Chemotherapy patients who develop neutropenia are at risk of developing febrile neutropenia, which is a medical emergency that requires immediate medical management. Febrile neutropenia has historically been treated through the use of prophylactic antibiotics, but their usefulness continues to be controversial and the incidence of febrile neutropenia continues to be high. The use of hematopoetic colony stimulating factors (CSFs) has improved the outcomes for patients who experience febrile neutropenia.
Real World Best Practices for DVT Prophylaxis (Accreditation Expired) Faculty:Paul E. Marik, MD, FCCP, FCCM | Arthur P. Wheeler, MD, FCCP | Jamie E. Siegel, MD | Sandra L. Kane-Gill, PharmD, MSc. CME Credit hours: 1.5 Venous thromboembolism (VTE) is a major cause of morbidity and mortality in the United States. There exists a gap in knowledge for the treatment of VTE with secondary prophylaxis, acute PE, as well as a special consideration for the critically ill (e.g. volume overloaded) or patients with comorbidities (e.g. renal insufficiency). Furthermore, the existing clinical data needs to be discussed and interpreted in order to be applied, as well as a discussion surrounding current issues and controversies in VTE treatment and prophylaxis. This program provides concise and contemporary insight addressing concerns practitioners have regarding the management of patients with VTE.
All information content within shall be considered confidential property of ArcMesa Educators, LLC
and should not be disclosed or redistributed to third parties without express permission.
Translating Evidence to Practice: A Case-Based Approach to VTE Prevention, Diagnosis & Management
Challenges in Dosing Low Molecular Weight Heparin
Chemotherapy-Induced Neutropenia: Impact, Risks & Prevention